Sex steroids are major promoters of the growth of breast and prostate cancers. This Review
by Poutanen et al. describes the development of treatments for these cancer types that act to …

Castration resistant prostate cancer (CRPC) remains androgen dependant despite castrate
levels of circulating testosterone following androgen deprivation therapy, the first line of …

Importance There is evidence that 5α-reductase inhibitors (5-ARIs), a standard treatment of
benign prostate hyperplasia, are associated with a decrease in the incidence of prostate …

While the exact etiology of prostate cancer remains elusive, various modifiable and
unmodifiable risk factors have been suggested as contributing factors. These include age …

Abstract Introduction and Objective Studies have linked Black race to prostate cancer (CaP)
risk but most fail to account for established risk factors such as 5-ARI use, prostate volume …

Background and objectives: Treatment of lower urinary tract symptoms (LUTS) related to
benign prostatic hyperplasia (BPH) has shifted over the last decades, with medical therapy …

Ethnopharmacological relevance Benign prostatic hyperplasia (BPH), characterized by
prostate enlargement due to cell proliferation, is a common urinary disorder in men over 50 …

Background α1-Adrenergic receptor antagonists are commonly used to treat benign
prostatic hyperplasia. Preclinical studies suggest that they induce cell death and inhibit …

Background 5-Alpha-reductase inhibitors (5-ARIs) have been suggested as potential
chemopreventive agents for prostate cancer (PCa). This study was conducted to evaluate …

Objectives To assess how the results of published national registry-based
pharmacoepidemiology studies (where select associations are of interest) compare with an …